News

“With MOSAIQ, Elekta brings proton therapy and radiation oncology expertise,” says Niek Schreuder, senior vice president of medical physics and technology at ProCure. “More importantly, Elekta shares ProCure’s

Once approved, Bristol-Myers Squibb will begin Phase I trial in Sweden. Bristol-Myers Squibb will pay a consideration of $4 million to AMRI, as a result of the submission

In addition, Jiangsu Yanshen has received a new medicine certificate from the PRC State Food and Drug Administration (SFDA) for its freeze-dried human use rabies vaccine (vero cell).

Ventilation care challenges such as treating respiratory failure from exacerbations of chronic obstructive pulmonary disease (COPD) while avoiding ventilator-associated pneumonia. Respironics V60 Ventilator This product provides traditional invasive

Cytokinetics will receive $50 million, and is expected to receive up to $600 million in future payments depending on the success of the drug, reported Reuters. Amgen has

The Medical Device Safety Act, introduced in March 2009, is aimed at reversing a 2008 US Supreme Court decision that found federal regulations preempt state-based liability claims challenging

Operating revenue Respiratory and acute care product group operating revenue increased by 34% to NZD244.5 million and OSA product group operating revenue increased by 23% to NZD202.6 million.

S. Kalyanasundaram, Managing Director, GlaxoSmithKline, India and Vice President of South Asia GSK International, said: “We are pleased to enter into this co-promotion agreement with Eisai to facilitate

FDA approval was based on safety and efficacy data from three pivotal trials with approximately 1,300 patients. The study demonstrated, patients taking Vimpat had their seizures reduced to